FindTrial
Sign In

A clinical trial to study the effect of Metformin in reducing weight gain induced by olanzapine in patients with psychiatric illness.

Metformin for treatment of olanzapine induced weight gain in adult patients with schizophrenia - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075301
Enrollment
64
Registered
2024-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F200- Paranoid schizophrenia

Interventions

Intervention1: Metformin: Metformin will be given to those patients newly started on Olanzapine for the treatment of schizophrenia. Route of administration - oral Dosage - 500 to 2000mg/day Frequen

Sponsors

Shadithya hospital private limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Schizophrenia and newly started on Olanzapine

Exclusion criteria

Exclusion criteria: Patients not tolerating Metformin Patients with history of renal disease, diabetes

Design outcomes

Primary

MeasureTime frame
WeightTimepoint: Weight at 15 days, 30 days and 90 days—

Secondary

MeasureTime frame
Waist circumference and Body mass indexTimepoint: Waist circumference and Body mass index at 15 days, 30 days and 90 days—

Countries

India

Contacts

Public ContactDr Soumya R S

Department of psychiatry, Shadithya hospital

soumyaramesan@gmail.com9497364991

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026